Compound Formula Rehmannia has been shown to be clinically effective in treating Parkinson＇s disease and levodopa-induced dyskinesia; however, the mechanisms remain unclear. In this study, we established a model of P...Compound Formula Rehmannia has been shown to be clinically effective in treating Parkinson＇s disease and levodopa-induced dyskinesia; however, the mechanisms remain unclear. In this study, we established a model of Parkinson＇s disease dyskinesia in rats, and treated these animals with Compound Formula Rehmannia. Compound Formula Rehmannia inhibited the increase in mRNA expression of N-methyl-D-aspartate receptor subunits 1 and 2 and excitatory amino acid neurotransmitter genes, and it inhibited the reduction in expression of γ-aminobutyric acid receptor B1, an inhibitory amino acid neurotransmitter gene, in the corpus striatum. In addition, Compound Formula Rehmannia alleviated dyskinesia symptoms in the Parkinson＇s disease rats. These experimental findings indicate that Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson＇s disease by modulating neurotransmitter signaling in the corpus striatum.展开更多
Objective:To investigate the effect of Shenqi Compound Formula (SCF) on peroxisome proliferators-activated receptor γ (PPARγ) in white adipose tissue of rats with macrovascular lesion in early stage of diabetes. Met...Objective:To investigate the effect of Shenqi Compound Formula (SCF) on peroxisome proliferators-activated receptor γ (PPARγ) in white adipose tissue of rats with macrovascular lesion in early stage of diabetes. Methods: Corresponding treatment was given to rats in model group, Ramipril group, normal control group, low dosage SCF group and high dosage SCF group respectively for 32 days. The expressions of PPARγ and adiponectin Messenger RNA (mRNA) were detected by real-time reverse transcriptase poly-merase chain reaction. Results: The expressions of PPARγ and adiponectin mRNA increased significantly in both low and high dosage SCF groups as compared with the model group, and a positive linear correlation was found between the expressions of PPARγ and adiponectin mRNA. Conclusions: SCF can prevent macrovascular lesion in early stage of diabetes, which is possibly related with up-regulating expressions of PPARγ and activating PPARγ.展开更多
Long-term application of levodopa （L-3, 4-dihydroxyphenylalanine, L-DOPA） for Parkinson＇s disease can lead to adverse effects and reduce the amount of dopamine transporter （DAT） in the corpus striatum. The presen...Long-term application of levodopa （L-3, 4-dihydroxyphenylalanine, L-DOPA） for Parkinson＇s disease can lead to adverse effects and reduce the amount of dopamine transporter （DAT） in the corpus striatum. The present study attempted to vedfy whether increasing the amount of DAT can reduce the adverse effects of L-DOPA. The specific radioactive uptake value of DAT in the corpus striatum of the lesioned hemisphere was significantly decreased, but was significantly increased following administration of compound rehmannia formula [Radix rehmanniae preparata （prepared rehmannia root）, Concha margantifera usta （nacre）, Radix paeoniae alba （white peony alba）, Radix salviae miltiotThizae （Danshen root）, Scorpio （scorpion）, green tea] for 4 weeks. The changes in DAT 1251-beta-carbomethoxy-3 beta-（4-iodophenyl） tropane autoradiography were consistent with those in radioactivity. The results revealed that the compound rehmannia formula can reduce the adverse effects of L-DOPA in treating Parkinson＇s disease, possibly by increasing the amount of DAT.展开更多
背景:肌萎缩侧索硬化为一种进行性神经退行性疾病,常导致大脑和脊髓神经元死亡。肌萎缩侧索硬化发病机制极为复杂,难治率、死亡率高且目前其治疗药物仅有2种,因此开发新治疗方法以改善患者预后迫在眉睫。目的:综述中药及间充质干细胞调...背景:肌萎缩侧索硬化为一种进行性神经退行性疾病,常导致大脑和脊髓神经元死亡。肌萎缩侧索硬化发病机制极为复杂,难治率、死亡率高且目前其治疗药物仅有2种,因此开发新治疗方法以改善患者预后迫在眉睫。目的:综述中药及间充质干细胞调控免疫反应治疗肌萎缩侧索硬化的作用机制。方法:以“traditional Chinese medicine,mesenchymal stem cells,ALS,immune response”为英文检索词,以“中药,间充质干细胞,肌萎缩侧索硬化,免疫反应”为中文检索词,检索万方、中国知网、PubMed及Web of Science数据库2010-2023年的相关文献,最终纳入69篇文献进行综述分析。结果与结论:①中药调控免疫反应治疗肌萎缩侧索硬化可总结为5个机制:主要包括冰片和黄芪甲苷等中药促进闭锁小带蛋白1、闭合蛋白5表达重建血液中枢神经系统屏障完整性;复方扶芳藤合剂调节自然杀伤细胞表面受体分子抑制其自身毒性;半枝莲和广藿香等作用补体系统因子抑制其异常激活;雷公藤和钩藤等介导细胞外信号调节激酶1/2衰减诱导型一氧化氮合酶产生而抑制小胶质细胞活化;左归丸、栝蒌根等促进白细胞介素10表达调控T细胞改善免疫环境。②通过现有研究总结了间充质干细胞调控免疫反应治疗肌萎缩侧索硬化可总结为5个机制:减少水通道蛋白4表达和降低内皮型一氧化氮合酶信号传导等方面修复免疫屏障完整性;释放吲哚胺2,3-双加氧酶和前列腺素E2等因子抗自然杀伤细胞毒性;分泌因子H干扰转化酶活性抑制补体系统异常激活;调控CX3CL1/CX3CR1系统轴或分泌转化生长因子β等途径改变小胶质细胞表型抑制其活性;增加白细胞介素10表达或激活STATS磷酸化通路来恢复T细胞功能。③目前中药联合间充质干细胞治疗肌萎缩侧索硬化研究较少,已知的相关研究报道显示,肌萎灵注射液可促进干细胞增殖分化以及补阳还五汤联合骨髓间充质干细胞显著提高血脑屏障完整性,未来还需进一步探讨两者对难治性肌萎缩侧索硬化的协同治疗效果。展开更多
基金supported by the National Natural Science Foundation of China,No.30672684,30973722Science and Technology Support Traditional Chinese Drug Research and Development Project of Shanghai,No.F50102+1 种基金Traditional Chinese Medicine Research Fund of Shanghai Municipal Health Bureau,No.2012J009AAnnual Research Budget of Shanghai University of Traditional Chinese Medicine in 2013,No.2013JW25
文摘Compound Formula Rehmannia has been shown to be clinically effective in treating Parkinson＇s disease and levodopa-induced dyskinesia; however, the mechanisms remain unclear. In this study, we established a model of Parkinson＇s disease dyskinesia in rats, and treated these animals with Compound Formula Rehmannia. Compound Formula Rehmannia inhibited the increase in mRNA expression of N-methyl-D-aspartate receptor subunits 1 and 2 and excitatory amino acid neurotransmitter genes, and it inhibited the reduction in expression of γ-aminobutyric acid receptor B1, an inhibitory amino acid neurotransmitter gene, in the corpus striatum. In addition, Compound Formula Rehmannia alleviated dyskinesia symptoms in the Parkinson＇s disease rats. These experimental findings indicate that Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson＇s disease by modulating neurotransmitter signaling in the corpus striatum.
文摘Objective:To investigate the effect of Shenqi Compound Formula (SCF) on peroxisome proliferators-activated receptor γ (PPARγ) in white adipose tissue of rats with macrovascular lesion in early stage of diabetes. Methods: Corresponding treatment was given to rats in model group, Ramipril group, normal control group, low dosage SCF group and high dosage SCF group respectively for 32 days. The expressions of PPARγ and adiponectin Messenger RNA (mRNA) were detected by real-time reverse transcriptase poly-merase chain reaction. Results: The expressions of PPARγ and adiponectin mRNA increased significantly in both low and high dosage SCF groups as compared with the model group, and a positive linear correlation was found between the expressions of PPARγ and adiponectin mRNA. Conclusions: SCF can prevent macrovascular lesion in early stage of diabetes, which is possibly related with up-regulating expressions of PPARγ and activating PPARγ.
基金the National Natural Science Foundation of China,No.30672684, 30973722the Third Intention Key Disciplinary Areas of Shanghai,No.S30302
文摘Long-term application of levodopa （L-3, 4-dihydroxyphenylalanine, L-DOPA） for Parkinson＇s disease can lead to adverse effects and reduce the amount of dopamine transporter （DAT） in the corpus striatum. The present study attempted to vedfy whether increasing the amount of DAT can reduce the adverse effects of L-DOPA. The specific radioactive uptake value of DAT in the corpus striatum of the lesioned hemisphere was significantly decreased, but was significantly increased following administration of compound rehmannia formula [Radix rehmanniae preparata （prepared rehmannia root）, Concha margantifera usta （nacre）, Radix paeoniae alba （white peony alba）, Radix salviae miltiotThizae （Danshen root）, Scorpio （scorpion）, green tea] for 4 weeks. The changes in DAT 1251-beta-carbomethoxy-3 beta-（4-iodophenyl） tropane autoradiography were consistent with those in radioactivity. The results revealed that the compound rehmannia formula can reduce the adverse effects of L-DOPA in treating Parkinson＇s disease, possibly by increasing the amount of DAT.
文摘背景:肌萎缩侧索硬化为一种进行性神经退行性疾病,常导致大脑和脊髓神经元死亡。肌萎缩侧索硬化发病机制极为复杂,难治率、死亡率高且目前其治疗药物仅有2种,因此开发新治疗方法以改善患者预后迫在眉睫。目的:综述中药及间充质干细胞调控免疫反应治疗肌萎缩侧索硬化的作用机制。方法:以“traditional Chinese medicine,mesenchymal stem cells,ALS,immune response”为英文检索词,以“中药,间充质干细胞,肌萎缩侧索硬化,免疫反应”为中文检索词,检索万方、中国知网、PubMed及Web of Science数据库2010-2023年的相关文献,最终纳入69篇文献进行综述分析。结果与结论:①中药调控免疫反应治疗肌萎缩侧索硬化可总结为5个机制:主要包括冰片和黄芪甲苷等中药促进闭锁小带蛋白1、闭合蛋白5表达重建血液中枢神经系统屏障完整性;复方扶芳藤合剂调节自然杀伤细胞表面受体分子抑制其自身毒性;半枝莲和广藿香等作用补体系统因子抑制其异常激活;雷公藤和钩藤等介导细胞外信号调节激酶1/2衰减诱导型一氧化氮合酶产生而抑制小胶质细胞活化;左归丸、栝蒌根等促进白细胞介素10表达调控T细胞改善免疫环境。②通过现有研究总结了间充质干细胞调控免疫反应治疗肌萎缩侧索硬化可总结为5个机制:减少水通道蛋白4表达和降低内皮型一氧化氮合酶信号传导等方面修复免疫屏障完整性;释放吲哚胺2,3-双加氧酶和前列腺素E2等因子抗自然杀伤细胞毒性;分泌因子H干扰转化酶活性抑制补体系统异常激活;调控CX3CL1/CX3CR1系统轴或分泌转化生长因子β等途径改变小胶质细胞表型抑制其活性;增加白细胞介素10表达或激活STATS磷酸化通路来恢复T细胞功能。③目前中药联合间充质干细胞治疗肌萎缩侧索硬化研究较少,已知的相关研究报道显示,肌萎灵注射液可促进干细胞增殖分化以及补阳还五汤联合骨髓间充质干细胞显著提高血脑屏障完整性,未来还需进一步探讨两者对难治性肌萎缩侧索硬化的协同治疗效果。
